This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects. http://www.researchmoz.us/rhabdomyosarcoma-pipeline-review-h1-2015-report.html

1. Rhabdomyosarcoma - Pipeline Review, H1 2015
Global Markets Directs, Rhabdomyosarcoma Pipeline Review, H1 2015, provides an overview of the Rhabdomyosarcomas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the
Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma Plan mergers
and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 4
introduction 5
global Markets Direct Report Coverage 5
rhabdomyosarcoma Overview 6
therapeutics Development 7
pipeline Products For Rhabdomyosarcoma - Overview 7
pipeline Products For Rhabdomyosarcoma - Comparative Analysis 8
rhabdomyosarcoma - Therapeutics Under Development By Companies 9
rhabdomyosarcoma - Therapeutics Under Investigation By Universities/institutes 10
rhabdomyosarcoma - Pipeline Products Glance 11
clinical Stage Products 11
rhabdomyosarcoma - Products Under Development By Companies 12
rhabdomyosarcoma - Products Under Investigation By Universities/institutes 13
rhabdomyosarcoma - Companies Involved In Therapeutics Development 14
bellicum Pharmaceuticals, Inc. 14
boehringer Ingelheim Gmbh 15
celgene Corporation 16
eisai Co., Ltd. 17
glaxosmithkline Plc 18
merrimack Pharmaceuticals, Inc. 19
neotropix, Inc. 20
novartis Ag 21
rhabdomyosarcoma - Therapeutics Assessment 22
assessment By Monotherapy Products 22
assessment By Target 23
assessment By Mechanism Of Action 25
assessment By Route Of Administration 27
Rhabdomyosarcoma - Pipeline Review, H1 2015

2. assessment By Molecule Type 29
drug Profiles 31
afatinib - Drug Profile 31
product Description 31
mechanism Of Action 31
r&d Progress 31
cell Therapy For Gd2 Expressing Solid Tumors - Drug Profile 35
product Description 35
mechanism Of Action 35
r&d Progress 35
celyvir - Drug Profile 36
product Description 36
mechanism Of Action 36
r&d Progress 36
dendritic Cell Therapy To Target Mage-a1, Mage-a3 And Ny-eso-1 For Oncology - Drug Profile 38
product Description 38
mechanism Of Action 38
r&d Progress 38
e-7438 - Drug Profile 39
product Description 39
mechanism Of Action 39
r&d Progress 39
everolimus - Drug Profile 41
product Description 41
mechanism Of Action 41
r&d Progress 41
irinotecan Sucrosofate Liposomal - Drug Profile 46
product Description 46
mechanism Of Action 46
r&d Progress 46
ntx-010 - Drug Profile 48
product Description 48
mechanism Of Action 48
r&d Progress 48
paclitaxel Albumin Bound - Drug Profile 50
product Description 50
mechanism Of Action 50
r&d Progress 50
pazopanib Hydrochloride - Drug Profile 53
product Description 53
mechanism Of Action 53
r&d Progress 53
rhabdomyosarcoma - Recent Pipeline Updates 58
rhabdomyosarcoma - Dormant Projects 84
rhabdomyosarcoma - Discontinued Products 85
appendix 86
methodology 86
coverage 86
secondary Research 86
primary Research 86
expert Panel Validation 86
contact Us 86
disclaimer 87
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Rhabdomyosarcoma - Pipeline Review, H1 2015

3. USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Rhabdomyosarcoma - Pipeline Review, H1 2015